Max Healthcare Institute Limited
Momentum (74/100) does the heavy lifting; valuation (2/100) is the drag.
ExpensiveOvervaluedMax Healthcare Institute Limited earns a Sell from StocksWizard, with a blended score of 44/100. We put fair value near ₹552.92; at ₹1,098.5 that leaves roughly 50% downside, so the stock screens overvalued by 50%. On 73.2x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 14% below its 52-week high of ₹1,271.64 and 18% above the low of ₹929.95. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9. The average analyst target of ₹1,147.72 implies about 4% upside across 25 analysts. It clears 8 of 13 investability checks, with durability 62, valuation 3 and momentum 74 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹442.33.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-13.62% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Sell44Piotroski F-score 7/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 14.3%
- Pass: Low debt (D/E < 0.5): 0.32x
- Fail: Positive free cash flow
- Pass: Revenue growth > 10%: 12%
- Pass: Earnings growing: 7%
- Pass: Net margin ≥ 10%: 17.2%
- Fail: Current ratio > 1.5: 0.89
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 10.46
- Pass: Piotroski ≥ 7: 7/9
Quarterly results
Annual financials
Shareholding
- Promoter27.1%
- Institutions61.8%
- Public & other11.0%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (17.2%).
- Financially solid — Altman Z 10.46.
- High Piotroski quality score (7/9).
Opportunities
- Revenue growing (12% YoY).
Bear case
Threats
- Rich valuation versus sector peers.
- Trades ~50% above our estimated fair value.
About Max Healthcare Institute Limited
Max Healthcare Institute Limited operates a multi-specialty hospital network in India, providing services across cardiology, orthopedics, oncology, neurology, general and minimal access surgery, pulmonology, obstetrics and gynecology, pediatrics, nephrology, gastroenterology, plastic and reconstructive surgery, organ transplants, and otolaryngology.
Max Healthcare Institute Limited — frequently asked questions
Is Max Healthcare Institute Limited a buy, hold or sell?
StocksWizard currently rates Max Healthcare Institute Limited (MAXHEALTH) a Sell, based on a blended score of 44/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Max Healthcare Institute Limited's fair value?
Our blended DCF and relative-valuation model estimates Max Healthcare Institute Limited's fair value at about ₹552.92, versus a current price of ₹1,098.5 — roughly 50% downside. On that basis the stock looks overvalued by 50%.
Is Max Healthcare Institute Limited financially healthy?
Max Healthcare Institute Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 7/9.
How has Max Healthcare Institute Limited's share price performed?
Max Healthcare Institute Limited is up 10% over three months, and last traded at ₹1,098.5. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.